ZEVRA THERAPEUTICS, INC.

ZVRA

ZEVRA THERAPEUTICS, INC.

ZVRA

Insider Sentiment (TTM):

Last Purchase:2025-09-12Last Sale:2026-06-22Shares Purchased (TTM):23,175Shares Sold (TTM):188,714

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:40,177,742Shares Outstanding:58,405,955Institutional Ownership Pct.:68.79%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	145	96	62	54	48	37	34	54	39	43	43	43
Available For Sale Securities Debt Securities Curr…	76	105	129	145	155	25	36	35	10	10	25	40
Notes And Loans Receivable Net Current	-	-	-	-	-	-	-	-	-	-	-	42
Other Short Term Investments	-	-	-	-	-	-	-	-	-	-	0	0
Accounts And Other Receivables Net Current	22	22	23	17	18	13	11	8	9	8	17	10
Prepaid Expense And Other Assets Current	5	5	7	7	4	4	4	2	3	2	2	2
Inventory Net	2	2	2	1	1	3	2	-	-	-	0	-
Assets Current	251	230	223	225	226	82	86	99	61	63	87	137
Available For Sale Securities Debt Securities Nonc…	39	36	48	31	15	6	6	6	-	-	0	-
Inventory Noncurrent	0	0	1	1	1	11	11	9	10	12	10	0
Property Plant And Equipment Net	1	0	0	0	1	0	0	1	1	1	1	1
Operating Lease Right Of Use Asset	2	1	1	1	1	2	1	1	1	1	1	1
Goodwill	5	5	5	5	5	5	5	5	5	5	5	-
Other Long Term Investments	-	-	-	-	-	-	-	-	-	-	0	0
Intangible Assets Net Excluding Goodwill	6	6	6	7	7	67	69	71	66	68	69	-
Other Assets Noncurrent	0	0	0	0	0	0	0	1	1	2	0	0
Assets	303	279	285	270	256	173	178	192	144	151	172	139
Liabilities And Stockhold…
Liabilities Current
Lines Of Credit Current	-	-	-	-	-	-	0	0	0	0	38	-
Accounts Payable And Accrued Liabilities Current	14	12	12	11	16	18	25	24	20	23	28	13
Operating Lease Liability Current	1	0	0	0	1	1	0	1	1	1	1	0
Accrued Income Taxes Current	21	20	14	-	-	-	0	-	-	-	-	-
Other Liabilities Current	1	1	1	9	7	3	2	1	3	2	3	0
Liabilities Current	49	47	39	26	29	27	34	34	30	30	74	22
Long Term Notes Payable	-	-	-	-	-	-	-	-	-	5	5	5
Long Term Line Of Credit	-	-	-	-	-	-	-	-	-	38	0	39
Long Term Debt Noncurrent	0	0	62	61	61	60	60	59	58	-	5	-
Accrued Income Taxes Noncurrent	7	7	7	17	17	16	14	-	-	-	0	-
Operating Lease Liability Noncurrent	1	1	1	1	1	1	0	0	1	1	0	1
Other Liabilities Noncurrent	2	2	2	4	3	5	5	6	7	9	7	0
Liabilities	85	73	130	137	139	132	138	122	112	102	110	72
Common Stock Value	-	-	-	-	-	0	0	0	0	0	0	0
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	-	0	-	-	-	-	-
Common Stock Value Outstanding	0	0	0	0	0	-	0	-	-	-	-	-
Additional Paid In Capital Common Stock	606	603	588	581	564	560	555	550	479	476	473	418
Treasury Stock Value	-11	-11	-11	-11	-11	-11	-11	-11	-11	-11	-11	-11
Retained Earnings Accumulated Deficit	-375	-384	-422	-434	-434	-508	-505	-470	-436	-416	-400	-339
Accumulated Other Comprehensive Income Loss Net Of…	-2	-2	-1	-2	-2	-0	1	-0	0	0	-0	-0
Stockholders Equity	218	206	155	133	117	41	40	70	32	49	62	62
Liabilities And Stockholders Equity	303	279	285	270	256	173	178	192	144	151	172	139
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	-	0	-	-	-	-	-
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	-	-	-	-	-
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	-	-	-	0	-
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	250	250	250	250	250	250	250	250	250	250	250	250
Common Stock Shares Issued	61	61	58	58	57	56	55	55	44	43	43	38
Shares Outstanding	59	59	57	56	55	55	54	53	42	42	42	36

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	3.02%	20.18%	-15.33%	-	-	-	-	-	-	-	-	-
2025	17.66%	23.76%	41.17%	-23.89%	-17.09%	-13.44%	-16.29%	-11.92%	-10.92%	3.07%	10.42%	27.08%
2024	-7.55%	-2.58%	23.66%	4.72%	3.00%	20.17%	5.66%	-0.81%	-9.47%	-11.11%	1.01%	7.95%
2023	-	-	-	-2.59%	-12.96%	-14.26%	12.73%	48.86%	35.80%	-12.40%	-9.69%	-15.50%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	5.17	4.89	5.68	8.62	7.85	3.02	2.53	2.88	2.00	2.10	1.18	6.31
Quick Ratio	5.02	4.74	5.46	8.29	7.66	2.79	2.35	2.82	1.91	2.04	1.15	6.23
Working Capital	202.67M	182.94M	183.73M	199.00M	197.51M	54.60M	51.96M	64.96M	30.44M	32.98M	13.22M	115.30M
Leverage & Debt
Debt to Equity	0.39	0.35	0.84	1.03	1.19	3.21	3.49	1.75	3.45	2.10	1.79	1.16
Interest Coverage TTM	14.43	-0.70	-7.89	-10.66	-14.04	-8.37	-11.84	-14.67	-18.86	-27.88	-33.05	-47.83
Debt Ratio	0.28	0.26	0.46	0.51	0.54	0.76	0.78	0.64	0.78	0.68	0.64	0.51
Efficiency & Turnover
Asset Turnover TTM	0.49	0.54	0.46	0.37	0.31	0.25	0.13	0.15	0.19	0.21	0.19	0.13
Per Share Metrics
Diluted EPS TTM	0.95	2.06	1.45	0.63	0.05	-1.70	-2.28	-1.88	-1.59	-	-	-
Free Cash Flow Per Share TTM	0.55	0.20	-0.05	-0.43	-0.85	-1.14	-1.51	-1.46	-1.34	-1.10	-0.95	-0.64
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	95.46%	86.07%	84.52%	80.65%	71.96%	78.84%	68.59%	67.13%	75.13%	89.19%	89.28%	94.16%
Operating Profit Margin TTM	60.54%	-4.44%	-59.12%	-103.89%	-192.07%	-177.09%	-368.47%	-354.22%	-315.77%	-206.64%	-180.63%	-264.20%
Net Profit Margin TTM	42.82%	101.58%	78.17%	41.86%	4.26%	-226.64%	-446.85%	-366.14%	-282.01%	-178.47%	-167.69%	-212.39%
Growth Metrics
Net Revenue Growth (1Y)	119.40%	201.29%	350.91%	244.60%	161.81%	46.47%	-14.02%	47.85%	43.21%	195.67%	170.26%	54.49%
Net Income Growth (1Y)	2,103.59%	-235.04%	-178.88%	-139.40%	-103.96%	86.01%	129.13%	154.89%	112.58%	-6.51%	10.85%	-0.13%
EPS Growth (1Y)	1,940.62%	-225.07%	-165.96%	-133.66%	-103.03%	43.66%	75.63%	85.13%	71.98%	-22.87%	7.83%	-0.79%
Valuation Metrics
P/E TTM	14.56	4.38	5.95	15.06	182.53	-4.40	-3.66	-3.70	-3.07	-4.90	-5.04	-4.76
P/B TTM	3.90	2.64	3.20	4.00	4.12	9.88	9.72	4.76	6.32	4.96	3.75	2.72
P/S TTM	6.23	4.45	4.65	6.31	7.78	9.98	16.34	13.55	8.67	8.74	8.46	10.11
Market Cap	848.30M	544.34M	495.59M	532.10M	482.62M	405.18M	385.74M	331.79M	205.31M	242.32M	232.21M	167.37M
Enterprise Value	702.98M	448.75M	495.11M	538.97M	495.60M	427.93M	411.45M	336.66M	224.37M	204.53M	231.93M	129.18M
Calculated Values
Free Cash Flow TTM	32.56M	11.93M	-2.50M	-24.23M	-46.53M	-61.82M	-69.67M	-69.65M	-56.30M	-45.92M	-33.83M	-22.10M
Net Debt	-145.32M	-95.60M	-478.00K	6.87M	12.98M	22.75M	25.72M	4.87M	19.07M	-37.79M	-283.00K	-38.20M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-22Sale

Owner: Thompson, Rahsaan

Title: Chief Legal & Compliance

Shares: 34,557

Price/Share: $12.68

Value: $438,182.76

Shares Owned: 80,235

Relationship: Officer

Ownership: Direct

2026-05-11Sale

Owner: Thompson, Rahsaan

Title: Chief Legal & Compliance

Shares: 1,794

Price/Share: $11.30

Value: $20,272.20

Shares Owned: 48,125

Relationship: Officer

Ownership: Direct

2026-02-09Sale

Owner: Mcfarlane, Neil F.

Title: President and CEO

Shares: 14,625

Price/Share: $8.56

Value: $125,190.00

Shares Owned: 387,225

Relationship: Director,Officer

Ownership: Direct

2026-02-03Sale

Owner: Schafer, Joshua

Title: CCO

Shares: 10,500

Price/Share: $9.19

Value: $96,495.00

Shares Owned: 62,278

Relationship: Officer

Ownership: Direct

2026-02-03Sale

Owner: Sangiovanni, Timothy J.

Title: SVP, Finance & Corp Controller

Shares: 3,000

Price/Share: $9.18

Value: $27,540.00

Shares Owned: 29,590

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-22	Thompson, Rahsaan	Officer	Chief Legal & Compliance	Direct	Sale	34,557	12.68	$438,182.76	80,235	4
2026-05-11	Thompson, Rahsaan	Officer	Chief Legal & Compliance	Direct	Sale	1,794	11.30	$20,272.20	48,125	4
2026-02-09	Mcfarlane, Neil F.	Director,Officer	President and CEO	Direct	Sale	14,625	8.56	$125,190.00	387,225	4
2026-02-03	Schafer, Joshua	Officer	CCO	Direct	Sale	10,500	9.19	$96,495.00	62,278	4
2026-02-03	Sangiovanni, Timothy J.	Officer	SVP, Finance & Corp Controller	Direct	Sale	3,000	9.18	$27,540.00	29,590	4
2026-02-02	Mcfarlane, Neil F.	Director,Officer	President and CEO	Direct	Sale	91,000	9.38	$853,580.00	364,350	4
2026-01-30	Sangiovanni, Timothy J.	Officer	SVP, Finance & Corp Controller	Direct	Sale	1,750	8.82	$15,435.00	20,924	4
2026-01-30	Schafer, Joshua	Officer	CCO	Direct	Sale	3,375	8.83	$29,801.25	37,444	4
2026-01-30	Thompson, Rahsaan	Officer,Other	Chief Legal & Compliance	Direct	Sale	4,080	8.83	$36,026.40	49,919	4
2026-01-30	Quartel, Adrian W	Officer	Chief Medical Officer	Direct	Sale	4,533	8.83	$40,026.39	9,723	4
2025-10-10	Mcfarlane, Neil F.	Director,Officer	President and CEO	Direct	Sale	19,500	10.82	$210,990.00	222,016	4
2025-09-12	Shih, Alvin	Director	-	Direct	Purchase	20,000	7.89	$157,800.00	20,000	4
2025-09-12	Favorito, Tamara A	Director	-	Direct	Purchase	3,175	7.79	$24,733.25	3,894	4
2025-08-19	Bode, John B	Director	-	Direct	Purchase	5,000	9.17	$45,850.00	45,000	4
2025-06-26	Thompson, Rahsaan	Officer,Other	Chief Legal & Compliance	Direct	Sale	24,000	9.21	$221,040.00	42,666	4
2025-03-28	Watton, Corey Michael	Director	-	Direct	Purchase	300	7.84	$2,352.00	1,800	4
2025-03-19	Bode, John B	Director	-	Direct	Purchase	10,000	7.96	$79,600.00	40,000	4
2025-02-14	Mcfarlane, Neil F.	Director,Officer	President and CEO	Direct	Sale	30,544	8.05	$245,879.20	191,516	4
2025-02-13	Sangiovanni, Timothy J.	Officer	SVP, Finance & Corp Controller	Direct	Sale	3,000	7.86	$23,580.00	16,341	4
2025-02-13	Clifton, R. Laduane	Officer	CFO & Treasurer	Direct	Sale	11,000	7.86	$86,460.00	51,361	4
2025-02-13	Schafer, Joshua	Officer	CCO & EVP, Bus. Development	Direct	Sale	10,500	7.86	$82,530.00	29,486	4
2024-10-11	Watton, Corey Michael	Director	-	Direct	Purchase	500	7.92	$3,960.00	1,500	4
2024-07-17	Clifton, R. Laduane	Officer	CFO & Treasurer	Direct	Purchase	2,000	6.77	$13,540.00	18,469	4
2024-07-16	Anderson, Thomas	Director	-	Direct	Purchase	10,000	6.81	$68,100.00	20,000	4
2024-07-12	Bode, John B	Director	-	Direct	Purchase	10,000	5.87	$58,700.00	30,000	4
2023-09-06	Clifton, R. Laduane	Officer	CFO, Secretary & Treasurer	Direct	Purchase	1,000	4.96	$4,960.00	15,309	4
2023-09-06	Anderson, Thomas	Director	-	Direct	Purchase	10,000	4.88	$48,800.00	10,000	4
2023-09-05	Bode, John B	Director	-	Direct	Purchase	10,000	5.13	$51,300.00	20,000	4
2023-09-05	Schafer, Joshua	Officer	CCO & EVP, Bus. Development	Direct	Purchase	500	5.13	$2,565.00	3,500	4
2023-06-23	Watton, Corey Michael	Director	-	Direct	Purchase	275	5.95	$1,636.25	1,000	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

68.79%

Inst. Shares: 40,177,742

Shares Outstanding: 58,405,955

2025-12-31

66.74%

Inst. Shares: 36,915,483

Shares Outstanding: 55,311,308

2025-09-30

68.68%

Inst. Shares: 38,429,874

Shares Outstanding: 55,951,572

2025-06-30

65.07%

Inst. Shares: 35,644,416

Shares Outstanding: 54,780,938

2025-03-31

63.24%

Inst. Shares: 34,211,349

Shares Outstanding: 54,095,543

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	40,177,742	58,405,955	68.79%
2025-12-31	36,915,483	55,311,308	66.74%
2025-09-30	38,429,874	55,951,572	68.68%
2025-06-30	35,644,416	54,780,938	65.07%
2025-03-31	34,211,349	54,095,543	63.24%
2024-12-31	33,129,391	46,251,239	71.63%
2024-09-30	28,008,677	47,808,817	58.58%
2024-06-30	15,282,719	41,899,087	36.48%
2024-03-31	12,883,007	41,778,774	30.84%
2023-12-31	11,668,439	35,452,460	32.91%
2023-09-30	9,917,700	34,724,614	28.56%
2023-06-30	7,334,226	33,898,233	21.64%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

ZEVRA THERAPEUTICS, INC. (ZVRA) — SEC Financial Statements & Analysis

ZEVRA THERAPEUTICS, INC. (ZVRA) is a pharmaceutical preparations company, incorporated in DE. ZEVRA THERAPEUTICS, INC. trades on Nasdaq as: ZVRA. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), ZEVRA THERAPEUTICS, INC. reported a 119.40% year-over-year revenue growth, a Gross Profit Margin of 95.46% (TTM), a Debt-to-Equity ratio of 0.39x, a Price-to-Sales (P/S) ratio of 6.23x (TTM), a Price-to-Book (P/B) ratio of 3.90x (TTM), at a market cap of $848.30M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 119.40%
Gross Profit Margin TTM: 95.46%
Debt To Equity: 0.39x
P/S TTM: 6.23x
P/B TTM: 3.90x
Market Cap: $848.30M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is ZEVRA THERAPEUTICS, INC. in?

ZEVRA THERAPEUTICS, INC. (ZVRA) operates in the Pharmaceutical Preparations industry.

What is ZVRA's market cap?

ZEVRA THERAPEUTICS, INC. (ZVRA) has a market capitalization of $848.30M as of 2026-06-30.

What is ZVRA's P/E ratio?

ZEVRA THERAPEUTICS, INC. (ZVRA)'s trailing twelve month P/E ratio is 14.56x as of 2026-06-30.

What exchange does ZVRA trade on?

ZEVRA THERAPEUTICS, INC. (ZVRA) trades on the Nasdaq.

Where is ZEVRA THERAPEUTICS, INC. incorporated?

ZEVRA THERAPEUTICS, INC. is incorporated in DE.